Evaluating the utility of a bioluminescent adp-detecting assay for lipid Kinases

Assay and Drug Development Technologies

Volumn 7, Issue 6, 2009, Pages 585-597

  Vidugiriene, Jolanta ^a   Zegzouti, Hicham ^a   Goueli, Said A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; LIPID; N,N DIMETHYLSPHINGOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE C; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2;

APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; EVALUATION; HIGH THROUGHPUT SCREENING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; VALIDITY;

ADENOSINE DIPHOSPHATE; CHEMISTRY TECHNIQUES, ANALYTICAL; LIPIDS; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; PHOSPHOTRANSFERASES; PROTEIN INTERACTION MAPPING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 76449095107     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0223     Document Type: Article

References (34)

1. Wymann MP, Schneiter R: Lipid signaling in disease. Nat Rev Mol Cell Biol 2008;9:162-176.
2. Sawyers C: Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
3. Vivanco I, Sawyers C: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
4. Foster FM, Traer CJ, Abraham SM, Fry MJ: The phosphoinositide (PI) 3-kinase family. J Cell Sci 2003;116:3037-3040.
5. Wenk MR: The emerging field of lipidomics. Nat Rev Drug Discov 2005;4: 594-610.
6. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharm 2008;8:393-412.
7. Ihle WT, Powis G: Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinical and toward cancer therapy. Mol Cancer Ther 2009;8:1-9.
8. Takabe K, Paugh S, Milstien S, Spiegel S: "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharma Rev 2008;60:181-195.
9. Brachmann S, Fritsch C, Maira S-M, Garcia-Echeverria C: PI3K and mTOR inhibitors-a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009;21:194-198.
10. Walker C, Thomas M, Edwards MJ: Phosphoinositide 3-kinase (PI3K) family of signaling enzymes and their role in asthma. Drug Disc Today 2006;3:63-69.
11. Xie P, Williams DS, Atilla-Gokcumen GE, Milk L, Xiao M, Smalley K, et al.: Structure-based design on organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. Chem Biol 2008;3:305-316.
12. Hong L, Quinn C, Jia Y: Evaluating the utility of the HTRF Transcreener ADP assay technology: A comparison with the standard HTRF assay technology. Anal Biochem 2009;391:31-38.
13. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD: Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596-603.
14. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhauser BS, Cantley LC: Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 1990;265:19704-19711.
15. Oliver A, Barlow KD, Spiegel S: Assaying sphingosine kinase activity. Methods Enzymol 2000;311:215-223.
16. Billich A, Ettmayer P: Fluorescence-based assay for sphingosine kinases. Anal Biochem 2004;326:114-119.
17. Roberts J, Moretti P, Darrow A, Derian C, Vadas M, Pitson S: An assay for sphingosine kinase activity using biotinylated sphingosine and streptavidin-coated membranes. Anal Biochem 2004;331:122-129.
18. Gray A, Olsson H, Batty I, Priganica L, Downes CP: Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003;313:234-245.
19. Guillou H, Lecureuuil C, Anderson KE, Suire S, Ferguson GJ, Ellson CD, et al.: Use of the GRP1 PH domain as a tool to measure the relative levels of PtdIns(3,4,5) P3 through a protein-lipid overlay approach. J Lipid Res 2007;48:726-732.
20. Klink T, Kleman-Leyer K, Kopp A, Westermeyer T, Lowery R: Evaluating PI3 kinase isoforms using Transcreener™ ADP assays. J Biomol Screen 2008;13:476-485.
21. Hong L, Quinn C, Jia Y: Evaluating the utility of the HTRF Transcreener ADP assay technology: A comparison with the standard HTRF assay technology. Anal Biochem 2009;391:31-38.
22. Zhang J-H, Chung T, Oldenburg K: A simple statistical parameter for use in evaluation and validation for high throughput screening assays. J Biomol Screen 1999;4:67-73.
23. Knight Z, Feldman M, Balla A, Balla T, Shokat K: A membrane capture assay for lipid kinase activity. Nat Protoc 2007;2:2459-2466.
24. Lingaraj T, Donovan J, Li Z, Doucette A, Harrison S, Ecsedy J, et al.: A highthroughput liposome substrate assay with automated lipid extraction process for PI 3-kinase. J Biomol Screen 2008;13:906-911.
25. Meier T, Cook J, Thomas J, Radding J, Horn C, Lingaraj T, et al.: Cloning, expression, Purification, and characterization of human Class Ia phosphoinositide 3-kinase isoforms. Protein Expr Purif 2004;35:218-224.
26. Lee K, Mwongela S, Kottegoda S, Borland L, Nelson A, Sims C, et al.: Determination of sphingosine kinase activity for cellular signaling studies. Anal Chem 2008;80:1620-1627.
27. Zegzouti H, Zdanovskaia M, Hsiao K, Goueli SA: ADP-Glo: A Bioluminescent and Homogeneous ADP Monitoring Assay for Kinases. Assay Drug Dev Technol 2009;In Press.
28. Stankewicz C, Rininsland F: A robust screen for inhibitors and enhancers of phosphoinositide-3-kinase (PI3K) activities by ratiometric fluorescence superquenching. J Biomol Screen 2006;11:413-422.
29. Knight ZA, Shokat KM: Features of selective kinase inhibitors. Chem Biol 2005;12:621-637.
30. Aller G, Carson J, Fernandes C, Lehr R, Sinnamon R, Kirkpatrick R, et al.: Characterization of PI3K class IA isoforms with regulatory subunit p55? using a scintillation proximity assay. Anal Biochem 2008;383:311-315.
31. Togame H, Dodo R, Inaoka T, Reinemer P: Development of a simple and robust assay to screen for inhibitors of sphingosine kinases. Assay Drug Dev Technol 2007;5:215-223.
32. Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y: N,N,-Dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-Phosphate activity in human platelets. Biochemistry 1996;35:626-633. (Pubitemid 26032716)
33. Manna D, Albanese A, Park WS, Cho W: Mechanistic basis of differential cellular responses of phosphatidylinositol 3,4-bisphosphate-and phosphatidylinositol 3,4,5-triphosphate-binding pleckstrin homology domains. J Biol Chem 2007;282:32093-32105.
34. Auld DS, Zhang Y-Q, Southall NT, Rai G, Landsman M, Maclure J, et al.: A basis for reduced chemical library inhibition of firefl y luciferase obtained from directed evolution. J Med Chem 2009;52:1450-1458.